ClinicalTrials.gg
RecruitingNCT05847179Updated Oct 5, 2026

Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome

A Phase 2 interventional study of Progerinin in Werner Syndrome, sponsored by PRG Science & Technology Co., Ltd.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by PRG Science & Technology Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 5, 2026Now RecruitingFirst site in United States+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.

There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.

Read the detailed description

Subjects who have successfully completed the Screening phase will enter the baseline and treatment phase of the study. Subjects will take the assigned treatment of Progerinin (2400 mg) split as 1200 mg BID in the morning and evening with food for 1-Year.

To evaluate the safety and tolerability of Progerinin for the treatment of BMD loss in subjects with typical Werner syndrome.

The secondary objectives of this study are:

  • To characterize the activity of Progerinin on bone metabolism in subjects with typical Werner Syndrome.
  • To evaluate vascular function in subjects with typical Werner Syndrome.
  • To evaluate glucose metabolism and insulin resistance in subjects with typical Werner Syndrome.
  • To evaluate lipid metabolism in subjects with typical Werner Syndrome.
  • To evaluate physical function in subjects with typical Werner Syndrome.
  • To evaluate the pharmacokinetics (PK) of Progerinin sachet administered twice daily (BID) in subjects with typical Werner Syndrome.
02

Conditions studied

  • Werner Syndrome
03

In context

Lead sponsor

PRG Science & Technology Co., Ltd. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

[Inclusion Criteria]

  1. Subjects must be at least ≥ 18 years of age.
  2. Subjects should have a confirmed diagnosis of typical Werner syndrome by genetic analysis.
  3. Subjects should be osteopenic (T-score between -1.0 and -2.5) or have confirmed osteoporosis (T-score ≤ -2.5) at screening/baseline. Subjects may continue to receive bone supplements (e.g., bisphosphonates, calcium supplements, Vitamin D supplements, etc.) as appropriate per standard of care throughout the study.
  4. Male or non-pregnant, non-lactating female.
  5. Subjects screening blood chemistry inclusive of metabolic panel, hematology, and urine analysis results should be acceptable to the investigator.
  6. Negative pregnancy test for female subjects as described below. Women of child bearing potential () and Women not of child-bearing potential are eligible to participate. Both women of childbearing potential and women of non-child-bearing potential should use an approved method of and agrees to continue to use this method for the duration of the study and for 90 days after last treatment.

    Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile or two years . All male subjects/partners must agree to use a In addition, subjects may not donate sperm for the duration of the study and for 90 days after last treatment.

    Females who are less than two (2) years post-menopausal, those with tubal ligations and those using contraception must have a negative serum pregnancy test at baseline within the one (1) week prior to the first study medication administration. Every six weeks, and at study termination a pregnancy test should be performed, either serum or urine stick test. However, if the urine result is positive, a serum pregnancy test will be performed.

  7. Provide signed written and willingness, ability to comply with study requirements.
  8. Subject must have a projected of ≥ 12 months in the opinion of the Investigator.

[Exclusion Criteria]

  1. Subject with clinical signs seen at screening are at the final stage of Werner syndrome progression, and completion of the study is difficult to be assessed, including:

    • Subjects who received continuous or intermittent home oxygen therapy for 6 months before obtaining consent
    • Subjects who received at least 2 hospitalizations for pneumonia during the 12 months prior to obtaining consent
    • Subjects who have at least 10% net weight loss and have not recovered. This includes significant net weight loss over the last six months.
  2. Subjects with significant dehydration as judged by the principal investigator.
  3. Subjects with pericardial fluid, ascites and pleural effusion.
  4. Therapy with drugs within 30 days of beginning study medication.
  5. History of prior , except for adequately treated in situ cancer, basal cell, squamous cell skin cancer, or other cancers (e.g., breast, prostate) for which the subject has been disease-free for at least 3 years.
  6. Any serious medical condition, laboratory abnormality, psychiatric illness, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for the study.
  7. Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous (IV) treatment for infection(s).
  8. Subjects with known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with (HIV).
  9. Subjects with a history of serious drug or allergic reaction such as anaphylaxis or any component of the formulation.
  10. bleeding within 2 weeks prior to baseline (e.g., gastrointestinal [GI] bleeding, intracranial hemorrhage).
  11. Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit and for the duration of the trial.
  12. Pregnant or lactating women.
  13. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube, or ), within 28 days prior to baseline or anticipated surgery during the study period.
  14. Inability to return for scheduled treatment and assessments.
  15. Subjects that require concomitant use of any medications or substances that are strong inhibitors or inducers of CYP2D6 or CYP2C8
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    all subjects will receive Progerinin 2400mg (1200mg twice daily) after morning and evening meals for a year

    Drug: Progerinin

Interventions

  • This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome. . There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)

    The intensity of the event will be graded using CTCAE v6.0 criteria

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  2. Incidence of Treatment-Related Adverse Events

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  3. Incidence of Serious Adverse Events (SAEs)

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  4. Incidence of TEAEs and SAEs leading to discontinuation of study medication

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  5. Changes in Blood Chemistry from Baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  6. Changes in Hematology from Baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  7. Changes in Urinalysis Results from Baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  8. Changes in Height (cm) from Baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  9. Changes in Weight (kg) from baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  10. Changes in Temperature (°C) from baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  11. Changes in Pulse Rate (beats per minute) from baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  12. Changes in Respiratory Rate (breaths per minute) from baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  13. Changes in Systolic Blood pressure (mmHg) from baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  14. Changes in Diastolic Blood pressure (mmHg) from baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  15. Changes in Physical Examination findings from baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  16. Change in ECG Ventricular Rate (beats per minute) from baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  17. Change in ECG PR interval (msec) from baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  18. Change in ECG QRS interval (msec) from baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  19. Change in ECG QT interval (msec) from baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

  20. Change in ECG QTc interval (msec) from baseline

    Time frame: Baseline to Week 56 (including 4-week follow-up)

Secondary outcomes

  1. Change in Femur Bone Mineral Density (BMD) from baseline

    Time frame: Baseline, Week 24, and Week 52

  2. Change in Lumbar Spine BMD from baseline

    Time frame: Baseline, Week 24, and Week 52

  3. Change in Aortic Pulse Wave Velocity (m/s) from baseline

    Time frame: Baseline, Week 24, and Week 52

  4. Change in Insulin Resistance by Oral Glucose Tolerance Test (OGTT) from baseline

    Time frame: Baseline, Week 24, and Week 52

  5. Change in Lipid Profile from baseline

    Time frame: Baseline, Week 24, and Week 52

  6. Change in Handgrip Strength Test from baseline

    Time frame: Baseline, Week 24, and Week 52

  7. Change in Short Physical Performance Battery (SPPB) Total Score from baseline

    Time frame: Baseline, Week 24, and Week 52

  8. Change in Ankle-Brachial Pressure Index (ABPI) from baseline

    Time frame: Baseline, Week 24, and Week 52

  9. Change in Bone-Specific Alkaline Phosphatase (BAP) from baseline

    Time frame: Baseline, Week 24, and Week 52

  10. Change in Osteocalcin (OC) from baseline

    Time frame: Baseline, Week 24, and Week 52

  11. Change in Procollagen Peptides (P1NP) from baseline

    Time frame: Baseline, Week 24, and Week 52

  12. Change in Deoxypyridinium (DPD) from baseline

    Time frame: Baseline, Week 24, and Week 52

  13. Change in C-Terminal Telopeptide of Type 1 Collagen (CTX) from baseline

    Time frame: Baseline, Week 24, and Week 52

  14. Pharmacokinetic Parameters of Progerinin at the Specified PK Assessment Visits

    Time frame: Baseline, Week12, Week 24, Week 36 and Week 52

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2023
First posted
May 6, 2023
StartEst.
Oct 2026was Jul 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
1 site added — first site in United States
Show site
  • University of Michigan · Ann Arbor, United States
Oct 5, 2026
Start date
Jul 2026→Oct 2026
Oct 5, 2026
Eligibility
1 criterion edited, 2 added
What changed in the criteria
  • Added[Inclusion Criteria]
  • EditedSubjects should be osteopenic (T-score between -1.0 and -2.5) or have confirmed osteoporosis (TscoreT-score ≤ -2.5) at screening/baseline. Subjects may continue to receive bone supplements (e.g., bisphosphonates, calcium supplements, Vitamin D supplements, etc.) as appropriate per standard of care throughout the study.
  • Added[Exclusion Criteria]
Oct 5, 2026
Primary outcomes
16 edited, 4 time frame changed, 2 removed, 1 description edited
What changed in the outcomes
  • EditedChanges in Blood Hemoglobin (g/dl)Chemistry from baselineBaselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChanges in Blood White Blood CellHeight (cell per microlitercm) from baselineBaselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChanges in Blood Platelets (cell per microliter)Hematology from baselineBaselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChanges in Serum CreatinineWeight (µmol/Lkg) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChanges in Serum Alanine Aminotransferase (IU/l)Urinalysis Results from baselineBaselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChanges in Serum Aspartate AminotransferaseTemperature (IU/l°C) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChanges in Serum Alkaline PhosphatasePulse Rate (microkatalbeats per literminute) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChanges in weightRespiratory Rate (kgbreaths per minute) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChanges in pulse rateSystolic Blood pressure (beats per minutemmHg) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChanges in respiratory rateDiastolic Blood pressure (breaths per minutemmHg) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChanges in temperature (°F)Physical Examination findings from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChange in ECG ventricular rate from baselineVentricular Rate (beats per minute) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChange in ECG PR interval (msec) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChange in ECG QRS interval (msec) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChange in ECG QT interval (msec) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • EditedChange in ECG QTc interval (msec) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
  • RemovedChanges in systolic Blood pressure (mm Hg) from baselineTime frame: week 54
  • RemovedChanges in Diastolic Blood pressure (mm Hg) from baselineTime frame: week 54
  • Time frameIncidence and severity of Treatment-Emergent Adverse Events (TEAEs)week 54 → Baseline to Week 56 (including 4-week follow-up)
  • Time frameIncidence of Treatment-Related Adverse Eventsweek 54 → Baseline to Week 56 (including 4-week follow-up)
  • Time frameIncidence of Serious Adverse Events (SAEs)week 54 → Baseline to Week 56 (including 4-week follow-up)
  • Time frameIncidence of TEAEs and SAEs leading to discontinuation of study medicationweek 54 → Baseline to Week 56 (including 4-week follow-up)
  • DescriptionIncidence and severity of Treatment-Emergent Adverse Events (TEAEs): how it is measured was reworded
Oct 5, 2026
Secondary outcomes
14 added
What changed in the outcomes
  • AddedChange in Femur Bone Mineral Density (BMD) from baselineTime frame: Baseline, Week 24, and Week 52
  • AddedChange in Lumbar Spine BMD from baselineTime frame: Baseline, Week 24, and Week 52
  • AddedChange in Aortic Pulse Wave Velocity (m/s) from baselineTime frame: Baseline, Week 24, and Week 52
  • AddedChange in Insulin Resistance by Oral Glucose Tolerance Test (OGTT) from baselineTime frame: Baseline, Week 24, and Week 52
  • AddedChange in Lipid Profile from baselineTime frame: Baseline, Week 24, and Week 52
  • AddedChange in Handgrip Strength Test from baselineTime frame: Baseline, Week 24, and Week 52
  • AddedChange in Short Physical Performance Battery (SPPB) Total Score from baselineTime frame: Baseline, Week 24, and Week 52
  • AddedChange in Ankle-Brachial Pressure Index (ABPI) from baselineTime frame: Baseline, Week 24, and Week 52
  • AddedChange in Bone-Specific Alkaline Phosphatase (BAP) from baselineTime frame: Baseline, Week 24, and Week 52
  • AddedChange in Osteocalcin (OC) from baselineTime frame: Baseline, Week 24, and Week 52
  • AddedChange in Procollagen Peptides (P1NP) from baselineTime frame: Baseline, Week 24, and Week 52
  • AddedChange in Deoxypyridinium (DPD) from baselineTime frame: Baseline, Week 24, and Week 52
  • AddedChange in C-Terminal Telopeptide of Type 1 Collagen (CTX) from baselineTime frame: Baseline, Week 24, and Week 52
  • AddedPharmacokinetic Parameters of Progerinin at the Specified PK Assessment VisitsTime frame: Baseline, Week12, Week 24, Week 36 and Week 52
Oct 5, 2026
Contact
Study contact changed: a•••@amarexcro.com · •••2531→c•••@kcrnresearch.com · •••2600. See the current contact
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • University of Michigan · Ann Arbor, United States
    Start date Jul 2026→Oct 2026
    Eligibility 1 criterion edited, 2 added
    What changed in the criteria
    • Added[Inclusion Criteria]
    • EditedSubjects should be osteopenic (T-score between -1.0 and -2.5) or have confirmed osteoporosis (TscoreT-score ≤ -2.5) at screening/baseline. Subjects may continue to receive bone supplements (e.g., bisphosphonates, calcium supplements, Vitamin D supplements, etc.) as appropriate per standard of care throughout the study.
    • Added[Exclusion Criteria]
    Primary outcomes 16 edited, 4 time frame changed, 2 removed, 1 description edited
    What changed in the outcomes
    • EditedChanges in Blood Hemoglobin (g/dl)Chemistry from baselineBaselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChanges in Blood White Blood CellHeight (cell per microlitercm) from baselineBaselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChanges in Blood Platelets (cell per microliter)Hematology from baselineBaselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChanges in Serum CreatinineWeight (µmol/Lkg) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChanges in Serum Alanine Aminotransferase (IU/l)Urinalysis Results from baselineBaselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChanges in Serum Aspartate AminotransferaseTemperature (IU/l°C) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChanges in Serum Alkaline PhosphatasePulse Rate (microkatalbeats per literminute) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChanges in weightRespiratory Rate (kgbreaths per minute) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChanges in pulse rateSystolic Blood pressure (beats per minutemmHg) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChanges in respiratory rateDiastolic Blood pressure (breaths per minutemmHg) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChanges in temperature (°F)Physical Examination findings from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChange in ECG ventricular rate from baselineVentricular Rate (beats per minute) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChange in ECG PR interval (msec) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChange in ECG QRS interval (msec) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChange in ECG QT interval (msec) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • EditedChange in ECG QTc interval (msec) from baselineTime frame: week 54 → Baseline to Week 56 (including 4-week follow-up)
    • RemovedChanges in systolic Blood pressure (mm Hg) from baselineTime frame: week 54
    • RemovedChanges in Diastolic Blood pressure (mm Hg) from baselineTime frame: week 54
    • Time frameIncidence and severity of Treatment-Emergent Adverse Events (TEAEs)week 54 → Baseline to Week 56 (including 4-week follow-up)
    • Time frameIncidence of Treatment-Related Adverse Eventsweek 54 → Baseline to Week 56 (including 4-week follow-up)
    • Time frameIncidence of Serious Adverse Events (SAEs)week 54 → Baseline to Week 56 (including 4-week follow-up)
    • Time frameIncidence of TEAEs and SAEs leading to discontinuation of study medicationweek 54 → Baseline to Week 56 (including 4-week follow-up)
    • DescriptionIncidence and severity of Treatment-Emergent Adverse Events (TEAEs): how it is measured was reworded
    Secondary outcomes 14 added
    What changed in the outcomes
    • AddedChange in Femur Bone Mineral Density (BMD) from baselineTime frame: Baseline, Week 24, and Week 52
    • AddedChange in Lumbar Spine BMD from baselineTime frame: Baseline, Week 24, and Week 52
    • AddedChange in Aortic Pulse Wave Velocity (m/s) from baselineTime frame: Baseline, Week 24, and Week 52
    • AddedChange in Insulin Resistance by Oral Glucose Tolerance Test (OGTT) from baselineTime frame: Baseline, Week 24, and Week 52
    • AddedChange in Lipid Profile from baselineTime frame: Baseline, Week 24, and Week 52
    • AddedChange in Handgrip Strength Test from baselineTime frame: Baseline, Week 24, and Week 52
    • AddedChange in Short Physical Performance Battery (SPPB) Total Score from baselineTime frame: Baseline, Week 24, and Week 52
    • AddedChange in Ankle-Brachial Pressure Index (ABPI) from baselineTime frame: Baseline, Week 24, and Week 52
    • AddedChange in Bone-Specific Alkaline Phosphatase (BAP) from baselineTime frame: Baseline, Week 24, and Week 52
    • AddedChange in Osteocalcin (OC) from baselineTime frame: Baseline, Week 24, and Week 52
    • AddedChange in Procollagen Peptides (P1NP) from baselineTime frame: Baseline, Week 24, and Week 52
    • AddedChange in Deoxypyridinium (DPD) from baselineTime frame: Baseline, Week 24, and Week 52
    • AddedChange in C-Terminal Telopeptide of Type 1 Collagen (CTX) from baselineTime frame: Baseline, Week 24, and Week 52
    • AddedPharmacokinetic Parameters of Progerinin at the Specified PK Assessment VisitsTime frame: Baseline, Week12, Week 24, Week 36 and Week 52
    Contact Study contact changed: a•••@amarexcro.com · •••2531→c•••@kcrnresearch.com · •••2600. See the current contact
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05847179
Lead sponsor
PRG Science & Technology Co., Ltd.
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Oct 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Christine Lee
Contact
christinelee@kcrnresearch.com
301-540-2600

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Progerinin

Start the discussion